These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26047697)

  • 1. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
    Huang J; Wang L; Cong Z; Amoozgar Z; Kiner E; Xing D; Orsulic S; Matulonis U; Goldberg MS
    Biochem Biophys Res Commun; 2015 Aug; 463(4):551-6. PubMed ID: 26047697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
    Shen Y; Rehman FL; Feng Y; Boshuizen J; Bajrami I; Elliott R; Wang B; Lord CJ; Post LE; Ashworth A
    Clin Cancer Res; 2013 Sep; 19(18):5003-15. PubMed ID: 23881923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
    Bajrami I; Frankum JR; Konde A; Miller RE; Rehman FL; Brough R; Campbell J; Sims D; Rafiq R; Hooper S; Chen L; Kozarewa I; Assiotis I; Fenwick K; Natrajan R; Lord CJ; Ashworth A
    Cancer Res; 2014 Jan; 74(1):287-97. PubMed ID: 24240700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    J Biochem Mol Toxicol; 2019 May; 33(5):e22286. PubMed ID: 30672063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
    Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
    Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
    Aoyagi-Scharber M; Gardberg AS; Yip BK; Wang B; Shen Y; Fitzpatrick PA
    Acta Crystallogr F Struct Biol Commun; 2014 Sep; 70(Pt 9):1143-9. PubMed ID: 25195882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H; Shi C; Yan Z; Li H
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
    Cai F; Ge I; Wang M; Biskup E; Lin X; Zhong X
    Tumour Biol; 2014 Apr; 35(4):3839-44. PubMed ID: 24337974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
    Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    Gan A; Green AR; Nolan CC; Martin S; Deen S
    Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
    Goldberg MS; Xing D; Ren Y; Orsulic S; Bhatia SN; Sharp PA
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):745-50. PubMed ID: 21187397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib, PARP1 inhibitor in ovarian cancer.
    Marchetti C; Imperiale L; Gasparri ML; Palaia I; Pignata S; Boni T; Bellati F; Benedetti Panici P
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1575-84. PubMed ID: 22788971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
    Kim J; Long KE; Tang K; Padanilam BJ
    Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.